Clinical Trial

Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-10.
Trial Details
NCT Number NCT07702955
Lead Sponsor Kangabio AUSTRALIA LTD PTY
Conditions Advanced or Metastatic Solid Tumors
Enrollment 85 participants
Start Date 2026-08
Primary Completion 2028-09 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-21